Loading...
Loading...
India's naproxen imports from GERMANY total $185.0K across 21 shipments from 6 foreign suppliers. MERCKLE GMBH leads with $182.7K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for naproxen โ a diversified sourcing base with multiple active suppliers from GERMANY.

MERCKLE GMBH is the leading Naproxen supplier from GERMANY to India, with import value of $182.7K across 12 shipments. The top 5 suppliers โ MERCKLE GMBH, NEUNCO PHARMACEUTICAL B.V., ILAPO, ILAPO INTERNATIONALE LUDWINGS-ARZNEIMITTEL, MERCKLE GMBH, โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MERCKLE GMBH | $182.7K | 12 | 98.7% |
| 2 | NEUNCO PHARMACEUTICAL B.V. | $1.7K | 1 | 0.9% |
| 3 | ILAPO | $363 | 2 | 0.2% |
| 4 | ILAPO INTERNATIONALE LUDWINGS-ARZNEIMITTEL | $158 | 1 | 0.1% |
| 5 | MERCKLE GMBH, | $135 | 2 | 0.1% |
| 6 | Merckle Gmbh | $24 | 3 | 0.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED | $182.8K | 14 | 98.8% |
| 2 | HETERO LABS LIMITED | $1.7K | 1 | 0.9% |
| 3 | HETERO LABS LIMITED |
GERMANY โ India trade corridor intelligence
The Germany to India trade corridor for pharmaceutical imports, including Naproxen formulations, is currently stable. Major ports like Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year, and the exchange rate between the Euro and the Indian Rupee has been favorable for importers. No significant disruptions have been reported in the supply chain, ensuring a reliable flow of goods between Germany and India.
The Indian government's Production Linked Incentive (PLI) scheme and other import substitution policies aim to boost domestic manufacturing and reduce dependency on imports, including finished pharmaceutical formulations. While these initiatives encourage local production, they also present challenges for importers, such as increased competition and potential changes in import regulations. Importers should monitor policy developments closely to adapt their strategies accordingly.
| $520 |
| 3 |
| 0.3% |
| 4 | TEVAPHARM INDIA PRIVATE LIMITED | $24 | 3 | 0.0% |
India and Germany share a robust trade relationship, with ongoing negotiations to enhance cooperation in various sectors, including pharmaceuticals. Discussions on Free Trade Agreements (FTAs) and mutual recognition of Good Manufacturing Practices (GMP) are underway to facilitate smoother trade flows. These efforts aim to streamline import procedures, reduce tariffs, and promote bilateral trade in pharmaceutical products.
The landed cost of importing Naproxen formulations from Germany to India includes the following components:
Importers should calculate the total landed cost by summing these components to determine the final cost per unit of the imported formulations.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Naproxen into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that both the manufacturing site and the product be registered. Applicants must submit a registration certificate and an import license application to the Drugs Controller General of India (DCGI). The registration certificate is valid for three years from the date of issue. The application process includes providing detailed product information, manufacturing licenses, and Good Manufacturing Practice (GMP) certificates. The timeline for obtaining import drug registration varies, but it typically involves several months of processing and evaluation.
Imported pharmaceutical formulations containing Naproxen must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life under India's climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. These inspections ensure that the formulations meet the required safety and efficacy standards before they are released into the Indian market.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical products, including mandatory import registration and licensing. These measures aim to prevent the sale of unapproved or illegal medicines in the Indian market. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined import procedures.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Naproxen formulations primarily due to the availability of patented or branded products, specialized dosage forms, and formulations not produced domestically. The domestic pharmaceutical industry may lack the capacity or technology to manufacture certain Naproxen formulations, leading to a reliance on imports. The market size for Naproxen formulations in India is substantial, with a growing demand driven by the increasing prevalence of conditions like arthritis and other inflammatory disorders.
The import duty structure for Naproxen formulations under HS Code 30049069 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10% on the BCD, and an Integrated Goods and Services Tax (IGST) of 12%. This results in a total landed duty of approximately 23.6%. Anti-dumping duties and exemptions may apply based on specific circumstances and trade agreements. Importers should consult the latest customs notifications and engage with customs brokers to ensure compliance with all applicable duties and taxes.
Germany is a preferred source for importing Naproxen formulations into India due to its strong pharmaceutical manufacturing sector, adherence to high-quality standards, and the availability of patented or specialized formulations not produced domestically. German manufacturers often offer formulations with advanced technology and quality assurance, providing a competitive edge in the Indian market. Other suppliers, such as those from China, the United States, and other European countries, also compete in this space, but Germany's reputation for quality and innovation positions it favorably.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Naproxen formulations from Germany due to the availability of patented or branded products, specialized dosage forms, and formulations not produced domestically. German manufacturers offer high-quality products that meet international standards, which are essential for treating conditions like arthritis and other inflammatory disorders prevalent in India.
When compared to other sources like China, the United States, and other European countries, Germany offers a competitive advantage in terms of product quality, adherence to international standards, and the availability of specialized formulations. While other countries may offer lower prices, Germany's reputation for quality and reliability makes it a preferred choice for importing pharmaceutical formulations into India.
Indian importers face several supply chain risks, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, ensure strict quality control measures, and maintain contingency plans for shipping disruptions.
Import license checklist, document requirements, quality testing, and compliance
5.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Naproxen suppliers from GERMANY to India include MERCKLE GMBH, NEUNCO PHARMACEUTICAL B.V., ILAPO. The leading supplier is MERCKLE GMBH with import value of $182.7K USD across 12 shipments. India imported Naproxen worth $185.0K USD from GERMANY in total across 21 shipments.
India imported Naproxen worth $185.0K USD from GERMANY across 21 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Naproxen sourced from GERMANY include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED, HETERO LABS LIMITED, HETERO LABS LIMITED. The largest buyer is ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED with $182.8K in imports across 14 shipments.
The total value of Naproxen imports from GERMANY to India is $185.0K USD, across 21 shipments and 6 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
21 Verified Shipments
6 suppliers, 4 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists